Posted by Michael Wonder on 15 Aug 2022
PHARMAC shares update on its assessment of Trikafta
15 August 2022 - PHARMAC has today published the latest record of advice from PTAC and, for the first time, has published a summary of how the agency has assessed Trikafta.
“Trikafta is a medicine we would like to fund, we have two proposals for it on our Options for Investment list for two different age groups, one for those 6 years and over and one for those 12 years and over,” says director of operations Lisa Williams. “We now have recommendations from both our Respiratory Advisory Committee and from PTAC that the medicine should be funded for people 6 years and over.”
